Mirzaei Siroos, Knoll Peter, Zandieh Shahin
Institut für Nuklearmedizin mit PET-Zentrum, Wilhelminenspital, Montleartstraße 37, 1160, Wien, Österreich.
Institut für Radiologie und Nuklearmedizin, Hanusch-Krankenhaus, Wien, Österreich.
Wien Med Wochenschr. 2019 Feb;169(1-2):12-14. doi: 10.1007/s10354-018-0668-5. Epub 2018 Oct 22.
Prostate cancer is the most frequent cancer type in men in industrialized countries. In case of biochemical recurrent disease of prostate cancer is molecular imaging with PET-CT or PET-MRI a very promising modality for the detection of local recurrence, lymph node involvement or distant metastasis. Of the so far implemented radiopharmaceuticals the radioactive labeled PSMA ligands (i. e. Ga-68 PSMA) have prevailed. There are also in the meanwhile treatment approaches with PSMA ligands (i. e. Lu-177 PSMA) in case of metastatic disease.
前列腺癌是工业化国家男性中最常见的癌症类型。对于前列腺癌生化复发的情况，PET-CT或PET-MRI分子成像在检测局部复发、淋巴结受累或远处转移方面是一种非常有前景的方式。在目前已应用的放射性药物中，放射性标记的PSMA配体（即Ga-68 PSMA）占了上风。与此同时，对于转移性疾病也有使用PSMA配体的治疗方法（即Lu-177 PSMA）。
